Correction

Figures & data

Table

Page	Original Language	Corrected Version Language
1 (Abstract-Methods)	56 lesions in 56 patients were treated with combination therapy via a single TACE session followed by one to three percutaneous cryoablation sessions twice a week (TACE-cryoablation group). A total of 54 lesions in 54 patients were treated with TACE alone for two to six sessions once a month (TACE group)	56 patients were treated with combination therapy via a single TACE session followed by one to three percutaneous cryoablation sessions twice a week (TACE-cryoablation group). A total of 54 patients were treated with TACE alone for two to six sessions once a month (TACE group)
2 (Study design)	Exclusion criteria were patients who had main portal vein obstruction, those with a secondary malignancy and those who underwent other treatment methods	Exclusion criteria were patients who had a secondary malignancy and those who underwent other treatment methods
4 (Tumor response)	The objective response rate for the TACE-cryoablation group was 42.9%, which was significantly higher than the 22.2% observed in the TACE group (p = .021).	The objective response rate for the TACE-cryoablation group was 48.2%, which was significantly higher than the 22.2% observed in the TACE group (p = .004).
4 (Table2)	The corrected version of Table 2 is given below (associated with the last correction).

Table 2. Tumor responses in different groups of tumor sizes for the two groups.

Tumor Response	All patients		Group A		Group B		Group C
	TACE-cryoablation	TACE	TACE-cryoablation	TACE	TACE-cryoablation	TACE	TACE-cryoablation	TACE
ORR	27	12	12	10	10	2	5	0
CR	4	0	4	0	0	0	0	0
PR	23	12	8	10	10	2	5	0
SD	23	20	2	3	7	10	14	7
PD	6	22	0	1	4	10	2	11
Total patients	56	54	14	14	21	22	21	18

Notes: Data are numbers of patients; CR: complete response; PR: partial response; SD: stable disease; PD: progressive response; ORR: objective response rate (CR + PR). p values (Pearson χ² test) were as follows: 0.004 for all patients, 0.357 for Group A (Fisher exact test), 0.005 for Group B, and 0.027 for Group C.